|
|
 |
|
Viewing report
|
|
|
|
Can New Therapies Unseat Traditional Chemotherapy Regimens in Acute Myelogenous Leukemia?
Decision Resources, Inc., April 2010, Pages: 56
With optimal standard chemotherapy, 70% of acute myelogenous leukemia (AML) patients enter remission; however, only 20% live to become long-term survivors, and the average time of AML-patient survival is merely 18 months. Despite the development and success of newer cancer therapies (such as monoclonal antibodies [MAbs]) for the treatment of other cancers, therapies to treat AML have varied little over the past few decades. Although the AML pipeline is rich with new agents (44 confirmed agents in Phase I-III development), these drugs face a steep uphill battle in proving they are at least as safe and efficacious as the numerous, less expensive chemotherapeutic agents that currently dominate the AML market.
Questions Answered in this Report
- An AML diagnosis is not always easy to determine initially because AML’s symptoms can appear to be caused by other ailments. How is the diagnosis of AML ultimately made? What kinds of diagnostic tests are used, and what biological markers are indicative of an AML diagnosis?
- Treatment of AML has changed very little in the past 30 years, with less expensive, generically available chemotherapies dominating the market. Why have no other agents challenged the commanding hold that chemotherapy has on the AML market? Is this positioning likely to change in the near term? What agents are in the clinical pipeline?
- Elderly AML patients (aged 60 or older) face an even more grim prognosis than their younger counterparts. What are the reasons for this poor prognosis? Is this poor prognosis a result of biological factors in this population? Is it compounded by comorbid conditions that occur primarily in the elderly?
- Acute promyelocytic leukemia (APL), a subset of AML, is remarkably curable, in stark contrast to the other subsets of AML. How does APL differ from AML? Why is APL easier to cure than AML?
Scope
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Primary research: Survey of 50 U.S. hematological oncologists.
- Epidemiology: Diagnosed, incident cases of AML; treatable pool (first-line and relapsed AML patients).
- Novel targets: Cyclin-dependent kinases; Bcl-2; Aurora kinases.
- Emerging therapies: Phase II: 26 drugs; Phase III: 5 drugs. Identification of 13 select Phase I and Phase I/II products.
Key Terms for this Report
Acute myelogenous leukemia (AML), Acute promyelocytic leukemia (APL), Acute leukemias, Consolidation therapy, Induction therapy, Bone marrow transplantation (BMT), Chemotherapy, Amonafide malate, Clolar (clofarabine), Dacogen (decitabine), Midostaurin, Onrigin (laromustine), Blood cancers
Customers who bought this item also bought
Acute Lymphocytic Leukemia - Unmet Needs in Adult and Pediatric Populations Drive Recent Market Developments
Leukemia Therapeutics Market (2010-2020) (Acute/Chronic lymphocytic leukemia & Acute/Chronic myeloid leukemia) Pipeline forecast & Market forecast in G8 countries
Leukemias: Principles and Practice of Therapy
Stakeholder Insight: Acute Leukemias - Reaching the Limits of Cytotoxic Chemotherapy
Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec
Pipeline Insight: Leukemias Underserved patient populations offer potential for market growth
Chronic Lymphocytic Leukemia: Off-Label Prescribing Drives Market Growth
Personalized Medicine - Scientific and Commercial Aspects
Drug Delivery in Cancer - Technologies, Markets and Companies
Future Oncology
|
|
|
|
